Compare Amgen, Inc. (AMGN) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $21.54. The key difference: Amgen, Inc. pays a 2.77% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none, and Amgen, Inc. is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| AMGN | CWEB | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $60.13 |
52-Week Low | $271.18 | $17.70 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $360.45, down 0.81% on the day, with a bullish technical signal from moving averages and strong fundamental performance including three consecutive quarterly EPS beats. Revenue grew to $36.75B in 2025 with a net income margin of 20.96%, though high debt levels and recent regulatory challenges for Tavneos in Europe present headwinds. Analyst sentiment is positive with 57.9% buy ratings and a consensus price target of $351.29.
The outlook for AMGN is cautiously optimistic, supported by earnings momentum and a diversified product portfolio, but investors face risks from patent expirations, competitive biosimilar pressures, and regulatory setbacks. The stock's current price near consensus target suggests limited near-term upside, requiring careful monitoring of pipeline developments and debt management.
CWEB trades at $21.93, down 0.63% on the day. Technical indicators show a bullish trend with moving averages supporting upside, though the 6-day RSI suggests overbought conditions near 85. The stock faces immediate resistance at $22 and support at $21. Recent corporate actions include a dividend scheduled for June 2026. Key financial ratios such as P/E and P/S are unavailable in the current dataset.
The outlook for CWEB hinges on upcoming financial disclosures to assess fundamentals. The bullish technical setup offers potential for gains if support holds, but high RSI indicates near-term consolidation risk. Investors should await earnings reports for clarity on profitability and valuation drivers amid limited recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
